The highly lucrative MERCK product brand name MEVACOR (natural substance named Lovastatin) looses patent protection soon. Merck stands to loose substantial revenues due to this. Yet, its widely know, as shown by the study below, done in 1992, and published in the British Journal of Cancer, the MEVACOR (lovastatin) when used in combination with another drug, ONCONASE, offers potent anti-cancer action. Yet, no action has been taken to develop this. As Mevacor starts to loose revenue as a cholesterol lowering drug, hopefully, Merck will finally wake up to profiting from the anti-cancer uses of MEVACOR (Lovastatin), which has been known for many years.
DEMAND MERCK WAKE UP AND SMELL THE COFFEE (or loose a lot of profit and potential.) It also might be nice to know WHY? WHY? WHY they haven't acted on this before now. Shareholders deserve some real, no b*llshit answers to this one.
All responses to go to: cocktailtime@yahoomail.com |
